Israeli biotech SME designing viral vectors and biological constructs for gene therapy and rare disease applications.
SynVaccine is a Tel Aviv-based biotech SME specializing in the rational design of viral-based biological products — originally focused on vaccine constructs, now extending into gene and cell therapy for rare diseases. Their core capability appears to be engineering viral vectors and biological systems using computational or structural design methods rather than empirical trial-and-error approaches. In H2020, they first validated this capability as a project coordinator under the SME Instrument, then joined a major European consortium (ARDAT) to apply their expertise to accelerating advanced therapy development. They occupy a niche at the intersection of viral engineering, therapeutic delivery, and rare disease biology.
The company name and their SME-1 project 'Rational Design and Construction of Viral Based Products' (SynVaccine, 2017) indicate this is their founding competence, carried forward into ARDAT where gene therapy vectors are central.
ARDAT (2020–2026) explicitly targets gene therapy R&D acceleration, and SynVaccine's viral design background is directly applicable to gene delivery vector development.
ARDAT lists cell therapy as a core keyword, suggesting SynVaccine contributes expertise or technology relevant to cell-based therapeutic platforms.
ARDAT is specifically oriented toward rare disease indications, placing SynVaccine within the orphan drug and advanced therapy regulatory and scientific context.
SynVaccine began in 2017 with a clear focus on rational design of viral products — language that points to vaccine-adjacent work, likely synthetic or computationally guided viral construct engineering. By 2020, their project participation had shifted entirely toward advanced therapies: gene therapy, cell therapy, and rare diseases, with no mention of vaccines. This suggests either a deliberate pivot from prophylactic to therapeutic applications, or an expansion of their viral design platform into gene delivery contexts where viral vectors are the primary tool. The direction is consistent: engineering viruses for biological effect, just with a more clinical and rare-disease-focused audience.
SynVaccine is moving from foundational viral engineering toward clinical advanced therapy applications — a consortium partner in this space should expect capabilities in viral vector design applied to therapeutic (not prophylactic) delivery contexts.
SynVaccine has acted as both coordinator (SME Instrument, solo-led feasibility project) and participant (large RIA consortium), which shows flexibility across collaboration formats. Their participation in ARDAT — a 35-partner consortium spanning 14 countries — suggests they are comfortable operating as a specialist contributor within large, internationally distributed teams. With only two projects in the record, it is too early to identify whether they gravitate toward any particular consortium structure, but their SME scale points to a specialist role rather than a project management hub.
SynVaccine has reached 35 unique consortium partners across 14 countries, almost entirely through their participation in the large ARDAT consortium. Their network is broad geographically but thin in history — it reflects one major collaboration rather than a built-up web of repeat partnerships.
SynVaccine is one of the few Israeli biotech SMEs with direct H2020 participation in both an SME Instrument project (as coordinator) and a major advanced therapy RIA consortium — making them a validated bridge between Israeli biotech and the European research and clinical ecosystem. Their specific angle — rational, design-driven construction of viral products — differentiates them from empirical vaccine or therapy developers and positions them as a platform technology company. For European consortia building advanced therapy programs, SynVaccine brings Israeli biotech network access combined with a focused viral vector design competence that is difficult to find at SME scale.
